AU2005319306B9 - Conserved HBV and HCV sequences useful for gene silencing - Google Patents

Conserved HBV and HCV sequences useful for gene silencing Download PDF

Info

Publication number
AU2005319306B9
AU2005319306B9 AU2005319306A AU2005319306A AU2005319306B9 AU 2005319306 B9 AU2005319306 B9 AU 2005319306B9 AU 2005319306 A AU2005319306 A AU 2005319306A AU 2005319306 A AU2005319306 A AU 2005319306A AU 2005319306 B9 AU2005319306 B9 AU 2005319306B9
Authority
AU
Australia
Prior art keywords
seq
sequences
hbv
dsrna
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005319306A
Other languages
English (en)
Other versions
AU2005319306A1 (en
AU2005319306B2 (en
Inventor
Liat Mintz
Catherine Pachuk
Chandrasekhar Satishchandran
Vincent Zurawski Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alnylam Pharmaceuticals Inc
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Publication of AU2005319306A1 publication Critical patent/AU2005319306A1/en
Assigned to ALNYLAM PHARMACEUTICALS, INC. reassignment ALNYLAM PHARMACEUTICALS, INC. Request for Assignment Assignors: NUCLEONICS, INC.
Application granted granted Critical
Publication of AU2005319306B2 publication Critical patent/AU2005319306B2/en
Publication of AU2005319306B9 publication Critical patent/AU2005319306B9/en
Priority to AU2012202085A priority Critical patent/AU2012202085B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Silicon Polymers (AREA)
AU2005319306A 2004-12-22 2005-12-20 Conserved HBV and HCV sequences useful for gene silencing Ceased AU2005319306B9 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012202085A AU2012202085B2 (en) 2004-12-22 2012-04-11 Conserved HBV and HCV sequences useful for gene silencing

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63829404P 2004-12-22 2004-12-22
US60/638,294 2004-12-22
PCT/US2005/046162 WO2006069064A2 (en) 2004-12-22 2005-12-20 Conserved hbv and hcv sequences useful for gene silencing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012202085A Division AU2012202085B2 (en) 2004-12-22 2012-04-11 Conserved HBV and HCV sequences useful for gene silencing

Publications (3)

Publication Number Publication Date
AU2005319306A1 AU2005319306A1 (en) 2006-06-29
AU2005319306B2 AU2005319306B2 (en) 2012-01-12
AU2005319306B9 true AU2005319306B9 (en) 2012-04-05

Family

ID=36602266

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005319306A Ceased AU2005319306B9 (en) 2004-12-22 2005-12-20 Conserved HBV and HCV sequences useful for gene silencing

Country Status (7)

Country Link
EP (2) EP2316942B1 (https=)
JP (3) JP2008525029A (https=)
AT (1) ATE507293T1 (https=)
AU (1) AU2005319306B9 (https=)
CA (1) CA2592099A1 (https=)
DE (1) DE602005027747D1 (https=)
WO (1) WO2006069064A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8575327B2 (en) * 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
JP2008514202A (ja) 2004-09-24 2008-05-08 ニュークレオニクス・インコーポレイテッド Ｒｎａｉによる一本鎖ウイルスの逆鎖複製中間体のターゲティング
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
PH12019502377A1 (en) 2011-04-21 2022-11-14 Isis Pharmaceuticals Inc Modulation of hepatitis b virus (hbv) expression
WO2013119793A1 (en) * 2012-02-07 2013-08-15 University Of Kansas Chemiluminescent nanoparticles and uses thereof
WO2013159109A1 (en) * 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
EP3363902B1 (en) * 2012-12-06 2019-11-27 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
CN105829537B (zh) * 2013-11-28 2020-09-22 巴法里安诺迪克有限公司 用于使用痘病毒载体诱导增强的免疫应答的组合物和方法载体
TWI710633B (zh) 2014-11-10 2020-11-21 美商阿尼拉製藥公司 Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法
CN107683336A (zh) * 2015-05-06 2018-02-09 贝尼泰克生物制药有限公司 用于治疗乙型肝炎病毒(hbv)感染的试剂及其用途
US11535851B2 (en) 2016-05-05 2022-12-27 Benitec IP Holdings Inc. Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
WO2018089914A1 (en) * 2016-11-11 2018-05-17 Alios Biopharma, Inc. Oligonucleotide targeting strategy for hbv cccdna
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
CA3106701A1 (en) 2018-08-13 2020-02-20 Alnylam Pharmaceuticals, Inc. Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643771A (en) 1980-05-19 1997-07-01 The Board Of Trustees Of The Leland Stanford Junior University Non-reverting live bacterial vaccines
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
JP2917998B2 (ja) 1988-02-05 1999-07-12 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 修飾された肝細胞およびその用途
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1995027788A1 (en) * 1994-04-11 1995-10-19 Dainabot Co., Ltd. Polypeptide derived from variant hepatitis b virus, gene encoding the same, and related dna
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US5932241A (en) 1995-06-07 1999-08-03 Valentis, Incorporated Cationic lipid DNA complexes for gene targeting
US5874565A (en) 1995-08-29 1999-02-23 Washington University Nucleic acids comprising a highly conserved novel 3 terminal sequence element of the hepatitis C virus
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
US5843770A (en) * 1996-03-11 1998-12-01 The Immune Response Corporation Antisense constructs directed against viral post-transcriptional regulatory sequences
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
EP1027074A1 (en) 1997-10-28 2000-08-16 American Home Products Corporation Compositions and methods for delivery of genetic material
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US5962482A (en) 1998-03-16 1999-10-05 The Procter & Gamble Company Method of reducing cellulite in mamalian skin
WO2000063364A2 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
EP1238061A2 (en) * 1999-11-24 2002-09-11 Pharmasset, Ltd. A new genotype of hepatitis b virus
CA2392853A1 (en) * 1999-12-03 2001-06-07 Innogenetics N.V. Hbv sequences
EP1229134A3 (en) 2001-01-31 2004-01-28 Nucleonics, Inc Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
AU2002250254A1 (en) * 2001-03-09 2002-09-24 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
DE10163098B4 (de) * 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
AU2003265935A1 (en) 2002-05-03 2003-11-17 Harman International Industries, Incorporated Sound detection and localization system
EP1540004A4 (en) 2002-07-31 2007-10-03 Nucleonics Inc DOUBLE-STRING RNA STRUCTURES AND CONSTRUCTS AND METHOD FOR THE PRODUCTION AND USE THEREOF
US7303906B2 (en) 2002-09-06 2007-12-04 Wisconsin Alumni Research Foundation Competent bacteria
AU2003284323A1 (en) 2002-10-18 2004-05-04 Alnylam Pharmaceuticals Inc Double-stranded rna structures and constructs, and methods for generating and using the same
EP2305812A3 (en) * 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
EP1571209B1 (en) * 2002-11-22 2012-06-13 Bio-Think Tank Co., Ltd. Method of detecting target base sequence of rna interference, method of designing polynucleotide base sequence causing rna interference, method of constructing double-stranded polynucleotide, method of regulating gene expression, base sequence processing apparatus, program for running base sequence
US6673661B1 (en) 2002-12-20 2004-01-06 Taiwan Semiconductor Manufacturing Co., Ltd. Self-aligned method for forming dual gate thin film transistor (TFT) device
WO2004063375A1 (en) * 2003-01-15 2004-07-29 Hans Prydz OPTIMIZING siRNA BY RNAi ANTISENSE
JP4545091B2 (ja) * 2003-01-24 2010-09-15 財団法人 東京都医学研究機構 Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸
EP1597351B1 (en) 2003-02-27 2012-04-18 Alnylam Pharmaceuticals Inc. METHODS AND CONSTRUCTS FOR EVALUATION OF RNAi TARGETS AND EFFECTOR MOLECULES
CN1257284C (zh) * 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 一种体外阻断乙肝病毒表达的方法
HUE042261T2 (hu) * 2003-06-12 2019-06-28 Alnylam Pharmaceuticals Inc Gén kikapcsolásra alkalmas konzervált HBV és HCV szekvenciák
US20050130919A1 (en) 2003-07-18 2005-06-16 University Of Massachusetts Regulatable promoters for synthesis of small hairpin RNA
WO2005007875A2 (en) 2003-07-18 2005-01-27 University Of Massachusetts Enhanced promoters for synthesis of small hairpin rna
CA2577519A1 (en) * 2004-08-23 2006-03-30 Nucleonics, Inc. Multiple rna polymerase iii promoter expression constructs
JP5671371B2 (ja) * 2011-03-01 2015-02-18 株式会社山本鉄工所 連続プレス装置
JP2015086965A (ja) 2013-10-31 2015-05-07 株式会社エクセディ フライホイール組立体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Hung et al (2004) FEBS Lett vol 560 pps 210-214 *
McCaffrey et al (2003) Nature Biotech vol 21 pps 639-344 *
Shlomai et al (2003) Hepatology vol 37 pps 764-770 *

Also Published As

Publication number Publication date
WO2006069064A3 (en) 2007-10-25
CA2592099A1 (en) 2006-06-29
WO2006069064A2 (en) 2006-06-29
AU2005319306A1 (en) 2006-06-29
DE602005027747D1 (de) 2011-06-09
JP2008525029A (ja) 2008-07-17
JP2015003913A (ja) 2015-01-08
JP2012223202A (ja) 2012-11-15
ATE507293T1 (de) 2011-05-15
AU2005319306B2 (en) 2012-01-12
JP5934310B2 (ja) 2016-06-15
EP1833967A2 (en) 2007-09-19
EP2316942B1 (en) 2021-04-21
EP1833967B1 (en) 2011-04-27
EP2316942A1 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
AU2004263832B2 (en) Conserved HBV and HCV sequences useful for gene silencing
US10982212B2 (en) Conserved HBV and HCV sequences useful for gene silencing
JP5934310B2 (ja) 遺伝子サイレンシングに有用なｈｂｖおよびｈｃｖ保存配列
EP1797185B1 (en) Targeting opposite strand replication intermediates of single-stranded viruses by rnai
AU2018200873B2 (en) Conserved HBV and HCV sequences useful for gene silencing
AU2013257445B2 (en) Conserved HBV and HCV sequences useful for gene silencing
AU2012202085A1 (en) Conserved HBV and HCV sequences useful for gene silencing

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ALNYLAM PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): NUCLEONICS, INC.

SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired